Company Overview - Shun Teng International Holdings Limited is a publicly listed company in Hong Kong, previously known as Yu Yao Tang Group Holdings Limited, and has been listed on the Hong Kong Stock Exchange since October 11, 2013 [3] - The company primarily engages in the sales, marketing, and distribution of health and beauty supplements and products in Hong Kong and China [3] Financial Performance - As of March 31, 2025, Shun Teng International reported total revenue of 189 million yuan, a year-on-year decrease of 12.96% [2] - The company recorded a net profit attributable to shareholders of -33.4461 million yuan, representing a significant year-on-year decline of 6447.29% [2] - The gross profit margin stood at 77.03%, while the debt-to-asset ratio was 53.15% [2] Stock Performance - As of July 28, the stock price of Shun Teng International closed at 0.032 HKD per share, reflecting an increase of 10.34% with a trading volume of 732,000 shares and a turnover of 23,100 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 9.38%, and since the beginning of the year, it has decreased by 6.45%, underperforming the Hang Seng Index, which has risen by 26.56% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 3.12 times, with a median of 6.67 times [2] - Shun Teng International's P/E ratio is -2.49 times, ranking 146th in the industry [2] - Comparatively, other companies in the industry have the following P/E ratios: Other Precision Pharmaceuticals at 1.27 times, Kingsray Biotechnology at 1.69 times, Dongrui Pharmaceutical at 3.35 times, Jilin Changlong Pharmaceutical at 6.39 times, and Dajian Health International at 6.67 times [2]

Company Overview - Shun Teng International Holdings (00932.HK) reported a closing price of HKD 0.033 per share, with a 10.0% increase and a trading volume of 3.328 million shares, totaling HKD 110,300, and a price fluctuation of 23.33% [1] - The company has experienced a cumulative increase of 25% over the past month, but a year-to-date decline of 3.23%, underperforming the Hang Seng Index, which has risen by 20.75% [2] Financial Performance - For the fiscal year ending March 31, 2025, Shun Teng International Holdings achieved total revenue of HKD 189 million, a year-on-year decrease of 12.96% [2] - The company reported a net profit attributable to shareholders of -HKD 33.4461 million, reflecting a significant decline of 6447.29% [2] - The gross profit margin stood at 77.03%, with a debt-to-asset ratio of 53.15% [2] Valuation and Industry Comparison - Currently, there are no institutional investment ratings for Shun Teng International Holdings [3] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 3.78 times, with a median of 6.52 times [3] - Shun Teng International Holdings has a P/E ratio of -2.57 times, ranking 143rd in the industry [3] - Comparatively, other companies in the sector have the following P/E ratios: - Jingyou Pharmaceutical (00858.HK): 0.85 times - Kingsray Biotechnology (01548.HK): 1.44 times - Dongrui Pharmaceutical (02348.HK): 3.05 times - Jilin Changlong Pharmaceutical (08049.HK): 5.86 times - Dajiankang International (02211.HK): 5.97 times [3] Corporate Background - Shun Teng International Holdings Limited is a publicly listed company in Hong Kong (stock code: 932), previously known as Yuyatang Group Holdings Limited, and has been listed on the Hong Kong Stock Exchange since October 11, 2013 [3] - The company primarily engages in the sales, marketing, and distribution of health and beauty supplements and products in Hong Kong and China [3]